We advised BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) in the sale of its orofacial therapeutic business, including its bone and tissue regeneration treatment, GEM 21S and related intellectual property, to Luitpold Pharmaceuticals, Inc., a division of Daiichi Sankyo Co. Ltd of Japan. Under the agreement Luitpold has agreed to pay BioMimetic approximately $45 million in cash, in addition to royalty payments based on sales of existing and future products in the dental and orofacial therapeutic fields.
The sale allows BioMimetic to refocus its business on the development and commercialization of its orthopedic and sports medicine products, GEM OS1 and GEM OS2.
This experience gained prior to joining Bass, Berry & Sims PLC.